• On May 7, 2026, Halozyme Therapeutics announced a global collaboration and license agreement granting GSK access to its ENHANZE drug delivery technology for developing and potentially commercializing subcutaneous versions of multiple oncology targets, including antibody drug conjugates, with Halozyme eligible for an upfront payment, milestones, and royalties on net sales.
• This deal marks Halozyme’s first ENHANZE partnership involving subcutaneous delivery of antibody drug conjugates, potentially broadening its technology’s use across complex cancer therapies and diversifying future royalty streams.
• Next, we will examine how this first ENHANZE antibody drug conjugate collaboration with GSK may reshape Halozyme’s investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Halozyme Therapeutics Investment Narrative Recap

To own Halozyme, you need to believe ENHANZE can remain a preferred subcutaneous delivery platform across multiple blockbuster biologics, with growing, diversified royalties offsetting its high partner and product concentration. The new GSK oncology and ADC deal appears additive to that thesis but does not immediately change the near term focus on partner launch execution and legal and pricing headwinds, which still look like the key catalyst and risk for the stock.

The upcoming Q1 2026 earnings release on May 11 sits in the background of this GSK announcement, as analysts were already expecting higher revenue and EPS. Alongside that, the appointment of Darren Snellgrove as CFO in June 2026 adds a new steward for capital allocation and communication just as Halozyme extends ENHANZE into more complex oncology uses, potentially amplifying how quickly new collaborations translate into visible financial results.

Yet while ENHANZE deal momentum looks encouraging, investors should also be aware of the concentration risk around a handful of major partners and what happens if...

Halozyme Therapeutics’ narrative projects $2.2 billion revenue and $1.1 billion earnings by 2029.

Uncover how Halozyme Therapeutics' forecasts yield a $85.78 fair value, a 34% upside to its current price.

Exploring Other Perspectives

More bullish analysts already expected Halozyme to reach about US$2.2 billion in revenue and US$1.1 billion in earnings by 2028, so this GSK deal could further support that more optimistic view on ENHANZE royalty durability and partner breadth, even though those forecasts and the legal and concentration risks they highlight were set before this announcement and may yet evolve.

Explore 5 other fair value estimates on Halozyme Therapeutics - why the stock might be worth just $85.78!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Find 48 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.